Eurobio-Scientific SA (FR:ALERS)
:ALERS
Want to see FR:ALERS full AI Analyst Report?
Top Page
Eurobio-Scientific SA
(ALERS)
Select Model
Select Model
Rating:57Neutral
Price Target:
€24.00
▼(-0.62% Downside)
Action:Reiterated
Date:05/12/26
The score is primarily supported by financial resilience from a strengthened balance sheet and ongoing positive cash generation, but it is held back by weaker recent profitability/cash flow trends and an expensive valuation (high P/E). Technical indicators are mixed and do not provide a strong positive catalyst.
Positive Factors
Strong Balance Sheet
Low leverage and a larger equity buffer materially improve financial resilience over the medium term. This reduces refinancing risk, supports investment in product development or targeted M&A, and gives management flexibility to navigate cyclical lab spending without immediate liquidity pressure.
Negative Factors
Eroded Profitability
Sharp narrowing of operating and net margins lowers the company's earnings power and reduces internal funds for growth. Persistently thin margins increase vulnerability to pricing pressure, input cost volatility and compress capacity to invest in R&D or expand commercial reach.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Balance Sheet
Low leverage and a larger equity buffer materially improve financial resilience over the medium term. This reduces refinancing risk, supports investment in product development or targeted M&A, and gives management flexibility to navigate cyclical lab spending without immediate liquidity pressure.
Read all positive factors
Eurobio-Scientific SA (ALERS) vs. iShares MSCI France ETF (EWQ)
Market Cap
€226.12M
Dividend YieldN/A
Average Volume (3M)968.00
Price to Earnings (P/E)50.9
Beta (1Y)-0.21
Revenue Growth9.08%
EPS Growth21.19%
CountryFR
Employees329
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.47
Shares Outstanding10,248,871
10 Day Avg. Volume1,061
30 Day Avg. Volume968
Financial Highlights & Ratios
PEG Ratio2.21
Price to Book (P/B)1.36
Price to Sales (P/S)1.48
P/FCF Ratio39.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.13
Revenue Forecast (FY)€175.90M
Eurobio-Scientific SA Business Overview & Revenue Model
Company Description
Eurobio Scientific Société anonyme designs, develops, and commercializes specialty diagnostic products in the areas of transplantation, infectious diseases, life-science, and cancer. The company offers Tetanus Quick Stick, a test that is used in e...
How the Company Makes Money
Eurobio Scientific makes money primarily by selling life-science and diagnostic products to laboratory customers, generating revenue from two main sources: (1) Proprietary and/or group-developed IVD assays and specialty diagnostics where the compa...
Eurobio-Scientific SA Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
74
Positive
Cash Flow
60
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 169.00M | 154.95M | 130.65M | 152.61M | 184.71M |
| Gross Profit | 68.40M | 71.95M | 57.49M | 65.04M | 97.44M |
| EBITDA | 19.70M | 20.40M | 24.55M | 40.49M | 79.63M |
| Net Income | 4.90M | 4.00M | 4.83M | 24.94M | 60.54M |
Balance Sheet | |||||
| Total Assets | 256.76M | 257.17M | 316.33M | 330.42M | 209.22M |
| Cash, Cash Equivalents and Short-Term Investments | 20.66M | 23.07M | 89.03M | 85.94M | 102.39M |
| Total Debt | 16.02M | 34.05M | 100.66M | 113.60M | 15.68M |
| Total Liabilities | 72.83M | 78.31M | 141.16M | 157.75M | 49.00M |
| Stockholders Equity | 183.92M | 178.85M | 175.17M | 172.34M | 159.91M |
Cash Flow | |||||
| Free Cash Flow | 6.28M | 13.45M | 22.71M | 39.01M | 63.61M |
| Operating Cash Flow | 18.85M | 16.70M | 26.77M | 41.85M | 65.46M |
| Investing Cash Flow | -12.89M | -10.74M | -318.00K | -141.76M | -5.47M |
| Financing Cash Flow | -8.16M | -72.09M | -23.50M | 82.31M | -23.75M |
Eurobio-Scientific SA Technical Analysis
Negative
24.15
Price Trends
22.68
Negative
23.23
Negative
24.03
Negative
Market Momentum
-0.22
Positive
49.20
Neutral
29.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALERS, the sentiment is Negative. The current price of 24.15 is above the 20-day moving average (MA) of 22.72, above the 50-day MA of 22.68, and above the 200-day MA of 24.03, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 49.20 is Neutral, neither overbought nor oversold. The STOCH value of 29.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALERS.
Eurobio-Scientific SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | €226.12M | 50.93 | 1.32% | ― | 9.08% | 21.19% | |
54 Neutral | €45.66M | -1.03 | -14.58% | ― | 0.87% | 46.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €24.95M | -5.20 | -17.18% | ― | 138.92% | 11.14% | |
48 Neutral | €33.43M | 1.19 | ― | ― | 7.43% | ― | |
48 Neutral | €206.94M | -1.75 | 59.08% | ― | 1.79% | 15.89% |
* Healthcare Sector Average
FR:ALERS
Eurobio-Scientific SA
22.60
-2.75
-10.85%
FR:ALMKT
MAUNA KEA TECHNOLOGIES
0.17
0.09
117.50%
FR:ALNOV
Novacyt
0.63
0.17
37.64%
FR:ALDMS
Diagnostic Medical Systems
1.29
0.24
22.86%
FR:ALIKO
Ikonisys SA
1.58
0.00
0.00%
FR:ALMDT
Median Technologies
5.50
3.24
143.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.